Impact of Drotrecogin alfa (activated) on Resource Use and Implications for Reimbursement

Selecting therapies in health care requires rigorous review of clinical and economic data. The financial implications of new clinical treatment options are an important component. The preferred method for evaluating the costs and effects of therapies is cost‐effectiveness analysis along with an esti...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacotherapy 2002-12, Vol.22 (12P2), p.216S-222S
Main Authors: Dasta, Joseph F., Cooper, Liesl M.
Format: Article
Language:English
Subjects:
Anti-Infective Agents - economics
Anti-Infective Agents - therapeutic use
APACHE
Cost-Benefit Analysis
Critical Care - economics
Humans
Protein C - economics
Protein C - therapeutic use
Recombinant Proteins - economics
Recombinant Proteins - therapeutic use
Reimbursement Mechanisms
Resource Allocation
Sepsis - drug therapy
Sepsis - pathology
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Selecting therapies in health care requires rigorous review of clinical and economic data. The financial implications of new clinical treatment options are an important component. The preferred method for evaluating the costs and effects of therapies is cost‐effectiveness analysis along with an estimation of utility associated with the life‐years gained. Preliminary reports suggest patients receiving drotrecogin alfa (activated) for severe sepsis have a faster resolution of cardiovascular and pulmonary dysfunction with minimal additional financial burden despite additional survivors. Furthermore, the reported cost/quality‐adjusted life‐year of $48,800 is consistent with many other common life‐saving measures. Recently approved new technology payments for hospitals treating patients with drotrecogin alfa (activated) minimize financial impact. Clinicians and administrators should work collaboratively to optimize the therapy of patients with severe sepsis, minimize the financial impact on the health care system, and maximize the utility of drotrecogin alfa (activated).
ISSN:0277-0008
1875-9114
DOI:10.1592/phco.22.18.216S.33703